Breadcrumb
Presentation Materials
A Phase I trial of BI 1810631, a HER2 inhibitor, as monotherapy in advanced or metastatic solid tumors with HER2 aberrations
Material Type: Poster
Biomarker analyses of the first-in-class SIRP-alpha immune checkpoint inhibitor BI 765063 in patients with advanced solid tumors
